- Home
- ADV vs CDNA Comparison
ADV vs CDNA Comparison
Compare ADV & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADV | CDNA |
|---|---|---|
| Founded | 1987 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.0M | 712.2M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | ADV | CDNA |
|---|---|---|
| Price | $0.86 | $19.32 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $2.00 | ★ $26.67 |
| AVG Volume (30 Days) | ★ 1.1M | 841.8K |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.22 |
| Revenue | ★ $3,502,796,000.00 | $357,998,000.00 |
| Revenue This Year | N/A | $14.11 |
| Revenue Next Year | $0.96 | $12.00 |
| P/E Ratio | ★ N/A | $16.01 |
| Revenue Growth | N/A | ★ 14.46 |
| 52 Week Low | $0.80 | $10.96 |
| 52 Week High | $3.20 | $25.95 |
Technical Indicators
Market Signals| Indicator | ADV | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 43.87 | 60.43 |
| Support Level | $0.80 | $19.21 |
| Resistance Level | $0.98 | $20.05 |
| Average True Range (ATR) | 0.07 | 0.89 |
| MACD | 0.02 | -0.07 |
| Stochastic Oscillator | 55.61 | 61.97 |
Price Performance
Historical ComparisonAbout ADV Advantage Solutions Inc.
Advantage Solutions Inc is a omnichannel retail solutions agency in North America, uniquely positioned at the intersection of consumer-packaged goods (CPG) brands and retailers.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.